SCHEMBL4815217

SCHEMBL4815217

CC(C)Oc1ccc2c(c1)CCC2=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.49
HSD17B10 Q99714 2/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
HRH3 Q9Y5N1 3/20 0.48
HSD17B1 P14061 1/20 0.44
MAOA P21397 2/20 0.43
MAP3K9 P80192 1/20 0.43
MAP3K11 Q16584 1/20 0.43
BRD4 O60885 1/20 0.42
BRPF1 P55201 1/20 0.42
ALDH1A1 P00352 2/20 0.42
GRM5 P41594 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6200904 0.91 MAOB (0.54) MAOBHSD17B10CASP1CASP7HRH3
SCHEMBL7953934 0.90 MAOB (0.55) MAOBMAOA
SCHEMBL3275944 0.90 MAOB (0.55) MAOBHSD17B1MAOA
SCHEMBL31638292 0.86 BRD4 (0.50) MAOBHSD17B10HRH3MAOABRD4
SCHEMBL17604746 0.83 MAOB (0.52) MAOBHSD17B10CASP1CASP7HRH3
SCHEMBL7389121 0.81 MAPT (0.49) MAOBHSD17B10CASP1CASP7HRH3
SCHEMBL30821349 0.81 MAPT (0.49) MAOBHSD17B10CASP1CASP7HRH3
SCHEMBL268592 0.80 KDM4E (0.56) MAOBHSD17B10CASP1CASP7HRH3
SCHEMBL30218157 0.79 METAP1 (0.46) MAOBHSD17B10BRD4BRPF1ALDH1A1
SCHEMBL9134852 0.79 MAOB (0.46) MAOBHSD17B10CASP1CASP7HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250205204-A1 Transcription Factor Brn2 Inhibitory Compounds for Use as Therapeutics THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2025-06-26 US disclosed
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US disclosed
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBVIE INC. 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors TK1, MAP3K19, MAP3K20 MAOB 3311/4885HSD17B10 3236/4885CASP1 1504/4885
US-20250205204-A1 Transcription Factor Brn2 Inhibitory Compounds for Use as Therapeutics BRDT, BRPF3, BRIX1 MAOB 4036/4885HSD17B10 3207/4885CASP1 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.